Megasoft Limited has informed the Exchange regarding Board meeting held on July 01, 2025.
SIGMAADV · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Megasoft Limited's board, at a meeting on July 1, 2025, approved the sale of its entire 36.52% holding in Extrovis AG, a Switzerland-based associate company, to Refex Life Sciences Private Limited. The deal is valued at US $15 million (approximately ₹128.40 crore), payable in one or more tranches and subject to foreign exchange fluctuations. The share purchase agreement is yet to be executed, and the company will seek shareholder approval via postal ballot. Since Extrovis is an associate company, the sale does not affect Megasoft's standalone financials, only its consolidated books.
Positive for shareholders — Megasoft is unlocking ~₹128 crore in cash from a non-core associate investment, which could strengthen its balance sheet. The transaction is not a related-party deal, but completion remains subject to definitive agreements and shareholder approval.